Balaxi Pharmaceuticals Ltd

Balaxi Pharmaceuticals Other Announcement

Balaxi Pharmaceuticals reported nil activity regarding the re-lodgement of physical share transfer requests for August 2026. This is a routine regulatory compliance filing.

Balaxi Pharmaceuticals Business Update

Balaxi Pharmaceuticals has received WHO-GMP certification for its first pharmaceutical formulation manufacturing facility in Telangana. The facility has commenced manufacturing initially approved products for international markets.

Balaxi Pharmaceuticals Management Change

Balaxi Pharmaceuticals Limited shareholders approved the re-appointment of Ms. Akshita Ostwal as an Independent Director for a second five-year term starting September 5, 2026.

Balaxi Pharmaceuticals Annual General Meeting

Balaxi Pharmaceuticals Limited held its 83rd Annual General Meeting on August 24, 2026. Shareholders voted on financial statements and director re-appointments during the proceedings.

Balaxi Pharmaceuticals Investor Presentation: Key Takeaways

Balaxi reported 14.1% YoY revenue growth in Q1 FY27, driven by market diversification and its first proprietary manufacturing facility. Strategy emphasizes backward integration in Latin America and Africa.

Balaxi Pharmaceuticals Q1 FY27 Results: Net Profit ₹1.3 Cr, Up 333.3% YoY

Balaxi Pharmaceuticals Ltd reported revenue from operations of ₹80.7 Cr (+14.1% YoY) and net profit of ₹1.3 Cr (+333.3% YoY) for Q1 FY27.

Key figure

Net profit ₹1.3 Cr · +333.3% YoY

Balaxi Pharmaceuticals Business Update

Balaxi Pharmaceuticals Limited has released its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report forms part of the company's Annual Report.

Balaxi Pharmaceuticals Annual General Meeting

Balaxi Pharmaceuticals Limited will hold its 83rd Annual General Meeting on August 24, 2026. The meeting will be conducted via video conferencing to transact ordinary and special business.

Balaxi Pharmaceuticals Board Meeting Date

Balaxi Pharmaceuticals will hold a board meeting on August 5, 2026, to consider and approve its unaudited standalone and consolidated financial results for the June 2026 quarter.

Balaxi Pharmaceuticals Results Correction

Balaxi Pharmaceuticals clarified reporting discrepancies in its March 2026 financial results. The company filed revised XBRL results to correct inadvertent errors in expense and income figures.